Search

Search Constraints

You searched for: Author/Creator Hancu, Nicolae

Search Results

1. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy. (September 2015)

2. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Issue 10184 (11th May 2019)

3. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. (12th April 2016)

4. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Issue 1 (14th July 2017)

5. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Issue 10193 (13th July 2019)

6. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Issue 10193 (13th July 2019)

7. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Issue 10193 (13th July 2019)

8. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study2. (6th May 2015)

9. Prevalence of dyslipidemia and its association with cardiometabolic factors and kidney function in the adult Romanian population: The PREDATORR study. Issue 1 (January 2019)

10. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Issue 2 (February 2020)